{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:40:41Z","timestamp":1792680041191,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s10815-022-02548-3","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T07:05:48Z","timestamp":1655795148000},"page":"1733-1738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5302-6330","authenticated-orcid":false,"given":"Sumiko","family":"Maristany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8792","authenticated-orcid":false,"given":"Adam S.","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-9200","authenticated-orcid":false,"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Adeleye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"issue":"6","key":"2548_CR1","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1002\/cncr.31862","volume":"125","author":"K Young","year":"2019","unstructured":"Young K, Shliakhtsitsava K, Natarajan L, et al. Fertility counseling before cancer treatment and subsequent reproductive concerns among female adolescent and young adult cancer survivors. Cancer. 2019;125(6):980\u20139. https:\/\/doi.org\/10.1002\/cncr.31862.","journal-title":"Cancer."},{"issue":"9744","key":"2548_CR2","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(10)60355-8","volume":"376","author":"M De Vos","year":"2010","unstructured":"De Vos M, Devroey P, Fauser BCJM. Primary ovarian insufficiency. Lancet. 2010;376(9744):911\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(10)60355-8.","journal-title":"Lancet."},{"issue":"19","key":"2548_CR3","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.3390\/ijms20194720","volume":"20","author":"X Hao","year":"2019","unstructured":"Hao X, Anast\u00e1cio A, Liu K, Rodriguez-Wallberg KA. Ovarian follicle depletion induced by chemotherapy and the investigational stages of potential fertility-protective treatments\u2014a review. Int J Mol Sci. 2019;20(19):4720. https:\/\/doi.org\/10.3390\/ijms20194720.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"2548_CR4","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.3390\/molecules25204764","volume":"25","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody\u2013drug conjugates for cancer therapy. Molecules. 2020;25(20):4764. https:\/\/doi.org\/10.3390\/molecules25204764.","journal-title":"Molecules."},{"key":"2548_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-020-00189-9","volume":"9","author":"L Li","year":"2020","unstructured":"Li L, Wang Y. Recent updates for antibody therapy for acute lymphoblastic leukemia. Exp Hematol Oncol. 2020;9:33. https:\/\/doi.org\/10.1186\/s40164-020-00189-9.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"2548_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1509277.","journal-title":"N Engl J Med"},{"key":"2548_CR7","unstructured":"Pfizer Inc. Besponsa (inotuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf. Revised August 2017. Accessed Sep 29, 2021."},{"key":"2548_CR8","unstructured":"U.S. Food and Drug Administration. NDA\/BLA multi-disciplinary review and evaluation: Besponsa (inotuzumab ozogamicin). 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761040Orig1s000MultidisciplineR.pdf. Accessed 29 Sep 2021."},{"key":"2548_CR9","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","volume":"117","author":"EF Chakravarty","year":"2011","unstructured":"Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499\u2013506.","journal-title":"Blood"},{"issue":"20","key":"2548_CR10","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","volume":"34","author":"EC Larsen","year":"2016","unstructured":"Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children\u2019s Oncology Group Study AALL0232. J Clin Oncol. 2016;34(20):2380\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.62.4544.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2548_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/OGX.0b013e318224e97b","volume":"66","author":"RT Fleischer","year":"2011","unstructured":"Fleischer RT, Vollenhoven BJ, Weston GC. The effects of chemotherapy and radiotherapy on fertility in premenopausal women. Obstet Gynecol Surv. 2011;66(4):248\u201354. https:\/\/doi.org\/10.1097\/OGX.0b013e318224e97b.","journal-title":"Obstet Gynecol Surv"},{"issue":"20","key":"2548_CR12","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2217\/fon-2016-0176","volume":"12","author":"G Bedoschi","year":"2016","unstructured":"Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333\u201344. https:\/\/doi.org\/10.2217\/fon-2016-0176.","journal-title":"Future Oncol"},{"key":"2548_CR13","first-page":"5876","volume":"51","author":"MA Ghetie","year":"1991","unstructured":"Ghetie MA, et al. Antitumor activity of Fab\u2019 and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 1991;51:5876\u201380.","journal-title":"Cancer Res"},{"issue":"10","key":"2548_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","volume":"41","author":"A Hamada","year":"2002","unstructured":"Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet. 2002;41(10):705\u201318. https:\/\/doi.org\/10.2165\/00003088-200241100-00002.","journal-title":"Clin Pharmacokinet"},{"key":"2548_CR15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.bbmt.2019.07.039","volume":"25","author":"M Ashizawa","year":"2019","unstructured":"Ashizawa M, et al. Updated clinical outcomes of hematopoietic stem cell transplantation using myeloablative total body irradiation with ovarian shielding to preserve fertility. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25:2461\u20137.","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"4","key":"2548_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.leukres.2005.08.014","volume":"30","author":"T Seshadri","year":"2006","unstructured":"Seshadri T, Hourigan MJ, Wolf M, Mollee PN, Seymour JF. The effect of the hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leuk Res. 2006;30(4):483\u20135. https:\/\/doi.org\/10.1016\/j.leukres.2005.08.014.","journal-title":"Leuk Res"},{"key":"2548_CR17","doi-asserted-by":"publisher","unstructured":"Maksimovic V, Pavlovic-Popovic Z, Vukmirovic S, et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol Biol Rep. 2020;47(6):4699\u201308.\u00a0https:\/\/doi.org\/10.1007\/s11033-020-05481-9","DOI":"10.1007\/s11033-020-05481-9"},{"key":"2548_CR18","first-page":"739","volume":"65","author":"RC Shamberger","year":"1981","unstructured":"Shamberger RC, Rosenberg SA, Seipp CA, Sherins RJ. Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma. Cancer Treat Rep. 1981;65:739\u201346.","journal-title":"Cancer Treat Rep"},{"key":"2548_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.fertnstert.2007.08.032","volume":"90","author":"B Oriol","year":"2008","unstructured":"Oriol B, et al. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve. Fertil Steril. 2008;90:1579\u201382.","journal-title":"Fertil Steril"},{"issue":"1","key":"2548_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/JOE-21-0209","volume":"252","author":"PC Xu","year":"2021","unstructured":"Xu PC, Luan Y, Yu SY, Xu J, Coulter DW, Kim SY. Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse. J Endocrinol. 2021;252(1):15\u201330. https:\/\/doi.org\/10.1530\/JOE-21-0209.","journal-title":"J Endocrinol"},{"key":"2548_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.coemr.2020.12.004","volume":"18","author":"LR Alesi","year":"2021","unstructured":"Alesi LR, Winship AL, Hutt KJ. Evaluating the impacts of emerging cancer therapies on ovarian function. Curr Opin Endocrine Metab Res. 2021;18:15\u201328. https:\/\/doi.org\/10.1016\/j.coemr.2020.12.004.","journal-title":"Curr Opin Endocrine Metab Res"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-022-02548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-022-02548-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-022-02548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:05:27Z","timestamp":1744203927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-022-02548-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1007\/s10815-022-02548-3","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient has consented to the submission of the case report to the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Amanda J. Adeleye is a stake holder in Carrot and a consultant for Flo Health. Wendy Stock serves on advisory boards for Pfizer for which she has received speaking honorarium. Neither of the remaining authors have any competing nor financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}